# **labcorp**

Testing will be performed at a Labcorp laboratory, including formerly branded Dianon Pathology.

#### Dianon Systems, Inc. 1 Forest Parkway Shelton, CT 06484 203-926-7100 800-328-2666 dianon.labcorp.com

DERMATOPATHOLOGY

P10203

CLIENT INFORMATION		BILLING	<b>NFORMATION</b> (fa	ice sheet & front a	and back of insurance o	ard must be attached)	
REQUESTING	NPI#	Bill:		Medicare		Patient 🔲 Workers Com	
PHYSICIAN REFERRING	NPI#	Patient Status:	Hospital Inpatient	Hospital Ou		-Hospital Patient	
PHYSICIAN	111 177	Insurance Inform					
				1			
		Insured Informati					
			Patient (circle one) Self	Spouse Cł	nild Other:		
		Primary Insuranc	Primary Insurance Co:		Authorizatio	Authorization #	
		Billing Address	Billing Address		Insured #		
		Billing City, State	Billing City, State, Zip		Group #		
		Secondary Insura	Secondary Insurance Co:		Authorization #		
PATIENT INFORMATION		Billing Address			Insured #		
		Billing City, State, Zip G					
Name (last, first, middle)		CLINICAL	INFORMATION				
Address		Collection Date: N	1M / DD /	YYYY	Time:	□ A.M. □ P.M.	
City, State, Zip		Number of Jars:					
Date of Birth: MM / DD / YYYY	Sex 🗆 M 🛛		ould be provided by the Symptoms in ICD-CM fo			horized designee. ghest Specificity Require	
Phone Number	Race:		NFORMATION ICD-C		ICD-CN		
MRN / PATIENT ID #	Chart #		100.0				
Physician/Authorized Signature:		ICD-CM	ICD-0	, IVI	ICD-CN	1	
H&E Histology (Gross & Microscopic) †		Consultation: (	a <i>diagnosis.</i> Dn referred slides <i>†</i> (send Referred material requiring			88323	
H&E Histology (Gross & Microscopic) †      (D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib     BRAF Gene Mutation Assay, Melanoma (481030) (send	prinogen, IgA, IgG, IgM, C3) ( <b>Michel's M</b> pathology report) 81210, 88381	edia) Consultation: (	On referred slides <i>†</i> (send	g slide prep † (se		88323	
<ul> <li>H&amp;E Histology (Gross &amp; Microscopic) <i>†</i></li> <li>(D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib</li> <li>BRAF Gene Mutation Assay, Melanoma (481030) (send</li> <li>BIOPSY DATA (please identify anatomic site</li> </ul>	prinogen, IgA, IgG, IgM, C3) ( <b>Michel's M</b> pathology report) 81210, 88381 p below and apply appropriate lai Specimen Ty	edia) Consultation: ( edia) Consultation: ( Histology Tech bel to jar) /pe	Dn referred slides † (send Referred material requirin Inical Component ロT	g slide prep <i>†</i> (se		Signs & Symptoms	
<ul> <li>□ H&amp;E Histology (Gross &amp; Microscopic) <i>†</i></li> <li>□ (D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib</li> <li>□ BRAF Gene Mutation Assay, Melanoma (481030) (send</li> </ul>	prinogen, IgA, IgG, IgM, C3) ( <b>Michel's M</b> pathology report) 81210, 88381 below and apply appropriate lai	edia) Consultation: ( edia) Consultation: ( Histology Tech bel to jar) /pe	On referred slides <i>†</i> (send Referred material requiring	g slide prep <i>†</i> (se		Signs & Symptoms	
<ul> <li>H&amp;E Histology (Gross &amp; Microscopic) <i>†</i></li> <li>(D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib</li> <li>BRAF Gene Mutation Assay, Melanoma (481030) (send</li> <li>BIOPSY DATA (please identify anatomic site</li> </ul>	prinogen, IgA, IgG, IgM, C3) ( <b>Michel's M</b> pathology report) 81210, 88381 p below and apply appropriate lai Specimen Ty	edia) Consultation: ( edia) Consultation: ( Histology Tech bel to jar) /pe	Dn referred slides † (send Referred material requirin nical Component ロT	g slide prep <i>†</i> (se		Signs & Symptoms	
H&E Histology (Gross & Microscopic) †     (D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib     BRAF Gene Mutation Assay, Melanoma (481030) (send     BIOPSY DATA (please identify anatomic site     Jar # Body Site/Descriptor     1	prinogen, IgA, IgG, IgM, C3) ( <b>Michel's M</b> pathology report) 81210, 88381 p below and apply appropriate lai Specimen Ty	edia) Consultation: ( edia) Consultation: ( Histology Tech bel to jar) /pe	Dn referred slides † (send Referred material requirin nical Component ロT	g slide prep <i>†</i> (se		Signs & Symptoms	
H&E Histology (Gross & Microscopic) †     (D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib     BRAF Gene Mutation Assay, Melanoma (481030) (send     BIOPSY DATA (please identify anatomic site     Jar # Body Site/Descriptor     1     2	prinogen, IgA, IgG, IgM, C3) ( <b>Michel's M</b> pathology report) 81210, 88381 p below and apply appropriate lai Specimen Ty	edia) Consultation: ( edia) Consultation: ( Histology Tech bel to jar) /pe	Dn referred slides † (send Referred material requirin nical Component ロT	g slide prep <i>†</i> (se		Signs & Symptoms	
H&E Histology (Gross & Microscopic) †     (D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib     BRAF Gene Mutation Assay, Melanoma (481030) (send     BIOPSY DATA (please identify anatomic site     Jar # Body Site/Descriptor     1	prinogen, IgA, IgG, IgM, C3) ( <b>Michel's M</b> pathology report) 81210, 88381 p below and apply appropriate lai Specimen Ty	edia) Consultation: ( edia) Consultation: ( Histology Tech bel to jar) /pe	Dn referred slides † (send Referred material requirin nical Component ロT	g slide prep <i>†</i> (se		Signs & Symptoms	
H&E Histology (Gross & Microscopic) †     (D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib     BRAF Gene Mutation Assay, Melanoma (481030) (send     BIOPSY DATA (please identify anatomic site     Jar # Body Site/Descriptor     1     2	prinogen, IgA, IgG, IgM, C3) ( <b>Michel's M</b> pathology report) 81210, 88381 p below and apply appropriate lai Specimen Ty	edia) Consultation: ( edia) Consultation: ( Histology Tech bel to jar) /pe	Dn referred slides † (send Referred material requirin nical Component ロT	g slide prep <i>†</i> (se		Signs & Symptoms	
H&E Histology (Gross & Microscopic) <i>†</i> (D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib     BRAF Gene Mutation Assay, Melanoma (481030) (send     BIOPSY DATA (please identify anatomic site     Jar # Body Site/Descriptor     1     2     3	prinogen, IgA, IgG, IgM, C3) ( <b>Michel's M</b> pathology report) 81210, 88381 p below and apply appropriate lai Specimen Ty	edia) Consultation: ( edia) Consultation: ( Histology Tech bel to jar) /pe	Dn referred slides † (send Referred material requirin nical Component ロT	g slide prep <i>†</i> (se		88323 Signs & Symptoms (see below for code)	
(D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib     BRAF Gene Mutation Assay, Melanoma (481030) (send     BIOPSY DATA (please identify anatomic site     Jar # Body Site/Descriptor     1     2     3     4     5	prinogen, IgA, IgG, IgM, C3) ( <b>Michel's M</b> pathology report) 81210, 88381 p below and apply appropriate lai Specimen Ty	edia) Consultation: ( edia) Consultation: ( Histology Tech bel to jar) /pe	Dn referred slides † (send Referred material requirin nical Component ロT	g slide prep <i>†</i> (se		Signs & Symptoms	
<ul> <li>H&amp;E Histology (Gross &amp; Microscopic) <i>f</i></li> <li>(D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib</li> <li>BRAF Gene Mutation Assay, Melanoma (481030) (send</li> <li>BIOPSY DATA (please identify anatomic site</li> <li>Jar # Body Site/Descriptor</li> <li>1</li> <li>2</li> <li>3</li> <li>4</li> </ul>	prinogen, IgA, IgG, IgM, C3) ( <b>Michel's M</b> pathology report) 81210, 88381 <b>below and apply appropriate lai</b> Specimen Ty (biopsy, excis	edia)       □ Consultation: (         edia)       □ Consultation: (         □ Histology Tech         bel to jar)         /pe         .ion)         □<	Dn referred slides <i>†</i> (send Referred material requiring Inical Component Clinical E	g slide prep <i>†</i> (se		Signs & Symptoms	
H&E Histology (Gross & Microscopic) <i>f</i> (D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib BRAF Gene Mutation Assay, Melanoma (481030) (send <b>BIOPSY DATA</b> ( <i>please identify anatomic site</i> Jar <i>#</i> Body Site/Descriptor   1   2   3   4   5   6   Signs and Symptoms (DO NOT CIRCLE. Write in app 1. Cyst 6. Plaque	prinogen, IgA, IgG, IgM, C3) (Michel's M pathology report) 81210, 88381 below and apply appropriate Iai Specimen Ty (biopsy, excis	edia)       □ Consultation: 6         edia)       □ Consultation: 6         □ Histology Tech         bel to jar)         /pe         ion)         □         0 </td <td>Dn referred slides <i>†</i> (send Referred material requiring Inical Component Clinical E</td> <td>g slide prep <i>†</i> (se</td> <td>end pathology report)</td> <td>Signs &amp; Symptoms</td>	Dn referred slides <i>†</i> (send Referred material requiring Inical Component Clinical E	g slide prep <i>†</i> (se	end pathology report)	Signs & Symptoms	
H&E Histology (Gross & Microscopic) †         (D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib         BRAF Gene Mutation Assay, Melanoma (481030) (send         BIOPSY DATA (please identify anatomic site         Jar #         Body Site/Descriptor         1         2         3         4         5         6         Signs and Symptoms (DO NOT CIRCLE. Write in appl         1. Cyst       6. Plaque         2. Keratosis       7. Scar	prinogen, IgA, IgG, IgM, C3) (Michel's M pathology report) 81210, 88381 below and apply appropriate Iai Specimen Ty (biopsy, excis plicable number for each corresp 11. Annular 1 12. Atrophy 1	Image: Consultation of Consultatin of Consultatin of Consultation of Consultati	Dn referred slides <i>t</i> (send Referred material requiring Inical Component T Clinical I Clinical I Ovided above.) 1. Pain 2. Photodistributed	26. Telanç I 27. Vesicla	piectasia 31.	Signs & Symptoms (see below for code)	
□ H&E Histology (Gross & Microscopic) †         □ (D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib         □ BRAF Gene Mutation Assay, Melanoma (481030) (send         BIOPSY DATA (please identify anatomic site         Jar #         Body Site/Descriptor         1         2         3         4         5         6         Signs and Symptoms (DO NOT CIRCLE. Write in app         1. Cyst       6. Plaque         2. Keratosis       7. Scar         3. Nodule       8. Scar/reexcisic	prinogen, IgA, IgG, IgM, C3) (Michel's M pathology report) 81210, 88381 below and apply appropriate lai Specimen Ty (biopsy, excis plicable number for each corresp 11. Annular 1 12. Atrophy 1 on 13. Bullae 1	Image: Consultation of Consultatin of Consultatin of Consultation of Consultati	Dn referred slides <i>t</i> (send Referred material requiring Inical Component The Clinical D Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C C Clinical D C C C C C C C C C C C C C C C C C C C	26. Telang 27. Vesicle 28. Ulcer	giectasia 31.	Signs & Symptoms (see below for code)	
□ H&E Histology (Gross & Microscopic) <i>f</i> □ (D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib         □ BRAF Gene Mutation Assay, Melanoma (481030) (send         BIOPSY DATA (please identify anatomic site         Jar #         Body Site/Descriptor         1         2         3         4         5         6         Signs and Symptoms (DO NOT CIRCLE. Write in appl         1. Cyst       6. Plaque         2. Keratosis       7. Scar         3. Nodule       8. Scar/reexcisic         4. Papule       9. Subcutaneous	prinogen, IgA, IgG, IgM, C3) (Michel's M pathology report) 81210, 88381 below and apply appropriate lai Specimen Ty (biopsy, excis plicable number for each corresp 11. Annular 1 12. Atrophy 1 on 13. Bullae 1 s Mass 14. Erythema 1	edia)       □ Consultation: 0         edia)       □ Consultation: 0         □ Histology Tech         bel to jar)         /pe         ion)         0 </td <td>Dn referred slides <i>t</i> (send Referred material requiring Inical Component T Clinical I Clinical I Ovided above.) 1. Pain 2. Photodistributed</td> <td>26. Telang 28. Ulcer 29. Debric</td> <td>giectasia 31.</td> <td>Signs &amp; Symptoms (see below for code)</td>	Dn referred slides <i>t</i> (send Referred material requiring Inical Component T Clinical I Clinical I Ovided above.) 1. Pain 2. Photodistributed	26. Telang 28. Ulcer 29. Debric	giectasia 31.	Signs & Symptoms (see below for code)	
□ H&E Histology (Gross & Microscopic) †         □ (D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib         □ BRAF Gene Mutation Assay, Melanoma (481030) (send         BIOPSY DATA (please identify anatomic site         Jar #         Body Site/Descriptor         1         2         3         4         5         6         Signs and Symptoms (D0 NOT CIRCLE. Write in appl         1. Cyst       6. Plaque         2. Keratosis       7. Scar         3. Nodule       8. Scar/reexcisic	prinogen, IgA, IgG, IgM, C3) (Michel's M pathology report) 81210, 88381 below and apply appropriate Ial Specimen Ty (biopsy, excis (biopsy, excis) plicable number for each corresp 11. Annular 1 12. Atrophy 1 on 13. Bullae 1 s Mass 14. Erythema 1 15. Excoriation 2	Image: Consultation of Consultatinatination of Consultation of Consultation of	Dn referred slides <i>t</i> (send Referred material requiring Inical Component The Clinical D Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C C Clinical D C C Clinical D C C C C C C C C C C C C C C C C C C C	26. Telang 28. Ulcer 29. Debric	giectasia 31. e	Signs & Symptoms (see below for code	
□ H&E Histology (Gross & Microscopic) †         □ (D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib         □ BRAF Gene Mutation Assay, Melanoma (481030) (send         BIOPSY DATA (please identify anatomic site         Jar #       Body Site/Descriptor         1       2         3       4         5       6         Signs and Symptoms (D0 NOT CIRCLE. Write in app         1. Cyst       6. Plaque         2. Keratosis       7. Scar         3. Nodule       8. Scar/reexcisic         4. Papule       9. Subcutaneous         5. Pigmented Neoplasm       10. Tag	prinogen, IgA, IgG, IgM, C3) (Michel's M pathology report) 81210, 88381 below and apply appropriate lau Specimen Ty (biopsy, excis plicable number for each corresp 11. Annular 1 12. Atrophy 1 on 13. Bullae 1 s Mass 14. Erythema 1 15. Excoriation 2 Addi	consultation: ( edia) Consultation: ( Histology Tech bel to jar) /pe ion) Consultation: ( Consultation: ( Histology Tech bel to jar) /pe ion) Consultation: ( Consultation: ( Histology Tech bel to jar) /pe ion) Consultation: ( Consultation: ( Consulta	Dn referred slides <i>t</i> (send Referred material requiring Inical Component The Clinical D Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C C Clinical D C C Clinical D C C C C C C C C C C C C C C C C C C C	26. Telang 28. Ulcer 29. Debric	giectasia 31. e	Signs & Symptoms (see below for code	
□ H&E Histology (Gross & Microscopic) f         □ (D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib         □ BRAF Gene Mutation Assay, Melanoma (481030) (send         BIOPSY DATA (please identify anatomic site         Jar #         Body Site/Descriptor         1         2         3         4         5         6         Signs and Symptoms (DO NOT CIRCLE. Write in app         1. Cyst       6. Plaque         2. Keratosis       7. Scar         3. Nodule       8. Scar/reexcisic         4. Papule       9. Subcutaneous         5. Pigmented Neoplasm       10. Tag	prinogen, IgA, IgG, IgM, C3) (Michel's M pathology report) 81210, 88381 below and apply appropriate lau Specimen Ty (biopsy, excis plicable number for each corresp 11. Annular 1 12. Atrophy 1 on 13. Bullae 1 s Mass 14. Erythema 1 15. Excoriation 2 Addi	consultation: ( edia) Consultation: ( Histology Tech bel to jar) /pe ion) Consultation: ( Consultation: ( Histology Tech bel to jar) /pe ion) Consultation: ( Consultation: ( Histology Tech bel to jar) /pe ion) Consultation: ( Consultation: ( Consulta	Dn referred slides <i>t</i> (send Referred material requiring Inical Component The Clinical D Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C C Clinical D C C Clinical D C C C C C C C C C C C C C C C C C C C	26. Telang 28. Ulcer 29. Debric	giectasia 31. e	Signs & Symptoms (see below for code	
□ H&E Histology (Gross & Microscopic) <i>f</i> □ (D9H-1) Direct Immunofluorescence, rule out Vasculitis (Fib         □ BRAF Gene Mutation Assay, Melanoma (481030) (send         BIOPSY DATA (please identify anatomic site         Jar #         Body Site/Descriptor         1         2         3         4         5         6         Signs and Symptoms (D0 NOT CIRCLE. Write in app         1. Cyst       6. Plaque         2. Keratosis       7. Scar         3. Nodule       8. Scar/reexcisic         4. Papule       9. Subcutaneous         5. Pigmented Neoplasm       10. Tag         MICROBIOLOGY       008649 □ Aerobic Bacterial Culture, Ger         008482 □ Fungus (Mycology) Culture       008573 □ Viral Culture, General	prinogen, IgA, IgG, IgM, C3) (Michel's M pathology report) 81210, 88381 below and apply appropriate Ial Specimen Ty (biopsy, excis plicable number for each corresp 11. Annular 1 12. Atrophy 1 on 13. Bullae 1 s Mass 14. Erythema 1 15. Excoriation 2 Mereral CPT 87070 CPT 87101 CPT 87252	consultation: ( edia) Consultation: ( Histology Tech bel to jar) /pe ion) Consultation: ( Consultation: ( Histology Tech bel to jar) /pe ion) Consultation: ( Consultation: ( Histology Tech bel to jar) /pe ion) Consultation: ( Consultation: ( Consulta	Dn referred slides <i>t</i> (send Referred material requiring Inical Component The Clinical D Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C Clinical D C C Clinical D C C Clinical D C C C C C C C C C C C C C C C C C C C	26. Telang 28. Ulcer 29. Debric	giectasia 31. e	Signs & Symptoms (see below for code	

1190L Rev. 10/25/2024 CT Lic # CL-0356

 $\textcircled{\sc 0}$  2024 Laboratory Corporation of America  $\textcircled{\sc 0}$  Holdings. All rights reserved.

\_\_\_\_

| | +

Patient, Client and Billing Information is requested for timely processing of this case. Medicare and other third party payors require that services be medically necessary for coverage, and generally do not cover routine screening tests.				
# = Medicare deems investigational. Medicare does not pay for services it deems investigational.	_			
Refer to Determining Necessity of ABN Completion on Reverse	Jar #	Jar #	Jar #	Jar #
SPECIMEN LABEL	Name:	Name:	Name:	Name:
INSTRUCTIONS:	Jar #	Jar #	Jar #	Jar #
	Name:	Name:	Name:	Name:
<ol> <li>Complete the requisition with all requested information.</li> </ol>	Jar #	Jar #	Jar #	Jar #
2.) Remove the required number of	Name:	Name:	Name:	Name:
labels from the front of this sheet.	Jar #	Jar #	Jar #	Jar #
<ol> <li>Place one (1) label on each specimen container (not on the lid).</li> </ol>	Name:	Name:	Name:	Name:

PLEASE DISPOSE OF UNUSED LABELS.

8910054923

+ | |

Form Number: 1190L Dermatopathology

ltem# 0081647

## **Test Combination/Panel Policy**

Labcorp's policy is to provide physicians, in each instance, with the flexibility to choose appropriate tests to assure that the convenience of ordering test combinations/panels does not distance physicians who wish to order a test combination/profile from making deliberate decisions regarding which tests are truly medically necessary. All the tests offered in test combinations/panels may be ordered individually using the Labcorp request form. Labcorp encourages clients to contact their local Labcorp representative or Labcorp location if the testing configurations shown here do not meet individual needs for any reason, or if some other combination of procedures is desired.

In an effort to keep our clients fully informed of the content, charges and coding of its test combinations/panels when billed to Medicare, we periodically send notices concerning customized test combinations/panels, as well as information regarding patient fees for all Labcorp services. We also welcome the opportunity to provide, on request, additional information in connection with our testing services and the manner in which they are billed to physicians, health care plans, and patients.

The CPT code(s) listed are in accordance with the current edition of *Current Procedural Terminology*, a publication of the American Medical Association. CPT codes are provided for the convenience of our clients; however, correct coding often varies from one carrier to another. Consequently, the codes presented here are intended as general guidelines and should not be used without confirming with the applicable payor that their use is appropriate in each case. All laboratory procedures will be billed to third-party carriers (including Medicare and Medicaid) at fees billed to patients and in accordance with the specific CPT coding required by the carrier. Microbiology CPT code(s) for additional procedures such as susceptibility testing, identification, serotyping, etc. will be billed in addition to the primary codes when appropriate. Labcorp will process the specimen for a Microbiology test based on source.

## Determining Necessity of Advance Beneficiary Notice of Non-coverage (ABN) Completion\*

- 1. **Diagnose.** Determine your patient's diagnosis.
- 2. Document. Write the diagnosis code(s) on the front of this requisition.
- 3. Verify. Determine if the laboratory test(s) ordered for the patient is subject to Local Coverage Determination or National Coverage Determination. This information can be located in the policies published by your Medicare Administrative Contractor (MAC), CMS, or www.Labcorp.com/MedicareMedicalNecessity.
- 4. **Review.** If the diagnosis code for your patient <u>does not</u> meet the medical necessity requirements set forth by Medicare or the test(s) is being performed more frequently than Medicare allows, an ABN should be completed.

\*An ABN should be completed for all tests that are considered investigational (experimental or for research use) by Medicare.

### How to Complete an Advance Beneficiary Notice of Non-coverage (ABN)

Medicare is very specific in requiring that all of the information included on the ABN be completed. Additionally, Labcorp requests that the specimen number or bar code label be included on the form. To be valid an ABN must:

- 1. Be executed on the CMS approved ABN form (CMS-R-131)
- 2. Identify the Medicare Part B Beneficiary, using the name as it appears on the patient's red, white and blue Medicare card
- 3. Indicate the test(s)/procedure(s) which may be denied within the relevant reason column
- 4. Include an estimated cost for the test(s)/procedure(s) subject to the ABN
- 5. Have 'Option 1', 'Option 2', or 'Option 3' designated by the beneficiary
- 6. Be signed **and** dated by the beneficiary or his/her representative **prior to** the service being rendered

### CPT Codes:

Direct Immunofluorescence (Fibrinogen, IgA, IgG, IgM, C3) 88346, 88350x4



Dianon Systems, Inc. is a subsidiary of Laboratory Corporation of America Holdings, using the brand Labcorp. 1190L Rev. 10/25/2024 CT Lic # CL-0356

© 2024 Laboratory Corporation of America® Holdings. All rights reserved.

\_\_\_\_

8910054923